Sunshine Biopharma Net Worth
Sunshine Biopharma Net Worth Breakdown | SBFM |
Sunshine Biopharma Net Worth Analysis
Sunshine Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sunshine Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sunshine Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sunshine Biopharma's net worth analysis. One common approach is to calculate Sunshine Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sunshine Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sunshine Biopharma's net worth. This approach calculates the present value of Sunshine Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sunshine Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sunshine Biopharma's net worth. This involves comparing Sunshine Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sunshine Biopharma's net worth relative to its peers.
To determine if Sunshine Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sunshine Biopharma's net worth research are outlined below:
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| Sunshine Biopharma may become a speculative penny stock | |
| The company reported the previous year's revenue of 34.87 M. Net Loss for the year was (5.13 M) with profit before overhead, payroll, taxes, and interest of 11.05 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (12.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Sunshine Biopharma Sees 18 percent Revenue Growth in Q1 2025 - TipRanks |
Sunshine Biopharma Quarterly Good Will |
|
Sunshine Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sunshine Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sunshine Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Sunshine Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sunshine Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sunshine Biopharma backward and forwards among themselves. Sunshine Biopharma's institutional investor refers to the entity that pools money to purchase Sunshine Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nordwand Advisors Llc | 2024-12-31 | 0.0 | Northwestern Mutual Wealth Management Co | 2025-03-31 | 0.0 | Altium Capital Management, Lp | 2025-03-31 | 50.5 K | Sbi Securities Co Ltd | 2025-03-31 | 5.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 3.8 K | Ubs Group Ag | 2024-12-31 | 868 | Bank Of America Corp | 2025-03-31 | 5.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 2.0 | Td Waterhouse Canada Inc | 2025-03-31 | 1.0 | Federation Des Caisses Desjardins Du Quebec | 2025-03-31 | 1.0 | Rise Advisors, Llc | 2025-03-31 | 1.0 |
Follow Sunshine Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.88 M.Market Cap |
|
Project Sunshine Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.24) | (0.23) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.22) | (0.21) |
When accessing Sunshine Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sunshine Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sunshine Biopharma's profitability and make more informed investment decisions.
Evaluate Sunshine Biopharma's management efficiency
Sunshine Biopharma has return on total asset (ROA) of (0.1178) % which means that it has lost $0.1178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2117) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 5th of June 2025, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to grow to -0.23. At this time, Sunshine Biopharma's Intangible Assets are very stable compared to the past year. As of the 5th of June 2025, Fixed Asset Turnover is likely to grow to 24.71, while Return On Tangible Assets are likely to drop (0.20).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 33.49 | 31.81 | |
| Tangible Book Value Per Share | 29.19 | 27.73 | |
| Enterprise Value Over EBITDA | 1.29 | 1.35 | |
| Price Book Value Ratio | 0.09 | 0.09 | |
| Enterprise Value Multiple | 1.29 | 1.35 | |
| Price Fair Value | 0.09 | 0.09 |
The strategic decisions made by Sunshine Biopharma management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 39.4772 | Revenue | Quarterly Revenue Growth 0.18 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sunshine Biopharma time-series forecasting models is one of many Sunshine Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sunshine Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Sunshine Biopharma Earnings per Share Projection vs Actual
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.76) | Revenue Per Share | Quarterly Revenue Growth 0.18 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.